Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
July 2019
-
Key Release
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both… -
Press Release
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies
Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures … -
Press Release
Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed
Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
June 2019
-
Press Release
Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis
New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]… -
Story People and Culture
Flexibility at Novartis: Christine Sturchler and Aileen Wrynn
Sturchler and Wrynn explain why their job-sharing experience was one of the most successful and energizing periods of their careers.
-
Press Release
Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis
Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in… -
Featured News
World Sickle Cell Day 2019
For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.
-
Press Release
New analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of… -
Press Release
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[… -
Press Release
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many… -
Press Release
Three quarters of people living with axial spondyloarthritis struggle to find a job, IMAS survey shows
New European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related… -
Press Release
Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…